Heavy chain constant regions with reduced binding to Fc gamma receptors
The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
1. An immunoglobulin heavy chain comprising a constant region, wherein amino acid positions 233-236 of a hinge domain are G, G, G and unoccupied; G, G, unoccupied, and unoccupied; G, unoccupied, unoccupied, and unoccupied; or all unoccupied, with amino acid positions numbered by EU numbering.
2. The immunoglobulin heavy chain of claim 1 that is human IgG4 isotype.
3. The immunoglobulin heavy chain of claim 1 , wherein amino acid positions 226-229 are CPPC.
4. The immunoglobulin heavy chain of claim 3 , wherein the hinge domain amino acid sequence comprises CPPCPAPGGG-GPSVF (SEQ ID NO:1), CPPCPAPGG--GPSVF (SEQ ID NO:2), CPPCPAPG---GPSVF (SEQ ID NO:3), or CPPCPAP----GPSVF (SEQ ID NO:4).
5. The immunoglobulin heavy chain of claim 1 , wherein the constant region has an amino acid sequence comprising SEQ ID NO:5, 6, 7 or 8 or a variant thereof having up to five insertions deletions, substitutions or insertions.
6. The immunoglobulin heavy chain of claim 1 , wherein the constant region comprises SEQ ID NO: 5, 6, 7 or 8.
7. The immunoglobulin heavy chain of claim 1 , wherein the constant region consists of SEQ ID NO: 5, 6, 7 or 8.
8. The immunoglobulin heavy chain of claim 1 comprising from N-terminal to C-terminal, amino acid positions 233-236 of the hinge domain, a CH2 domain and a CH3 domain.
9. The immunoglobulin heavy chain of claim 1 , comprising from N-terminal to C-terminal, a CH1 domain, the hinge domain, a CH2 domain and a CH3 domain.
10. The immunoglobulin heavy chain of claim 9 , wherein the CH1 domain, remainder of the hinge domain, if any, CH2 domain and CH3 domain are the same human isotype.
11. The immunoglobulin heavy chain of claim 9 , wherein the CH1 domain, remainder of the hinge domain, if any, CH2 domain and CH3 domain are human IgG1.
12. The immunoglobulin heavy chain of claim 9 , wherein the CH1 domain, remainder of the hinge domain, if any, CH2 domain and CH3 domain are human IgG2.
13. The immunoglobulin heavy chain of claim 9 , wherein the CH1 domain, remainder of the hinge domain, if any, CH2 domain and CH3 domain are human IgG4.
14. The immunoglobulin heavy chain of claim 1 , wherein the constant region has a CH3 domain modified to reduce binding to protein A.
15. The immunoglobulin heavy chain of any one of claim 1 , 8 or 9 , linked at the N-terminus to a heavy chain variable region.
16. The immunoglobulin heavy chain of claim 15 duplexed with an immunoglobulin light chain.
17. The immunoglobulin heavy chain of claim 15 duplexed with an immunoglobulin light chain as a heterodimer comprising two immunoglobulin heavy chains and two light chains.
18. The immunoglobulin of claim 17 , wherein the two heavy chains are the same.
19. The immunoglobulin of claim 17 , wherein the two heavy chains are different.
20. The immunoglobulin heavy chain of claim 1 , linked at the N-terminus to a binding polypeptide.
21. The immunoglobulin heavy chain of claim 20 linked via a linker to the binding polypeptide.
22. The immunoglobulin heavy chain of claim 20 , wherein the binding polypeptide is an extracellular domain.
23. The immunoglobulin heavy chain of claim 8 , wherein the remainder of the hinge domain, if any, CH2 domain and CH3 domain are each selected from the group consisting of human IgG1, human IgG2, human IgG3, and human IgG4.
24. The immunoglobulin heavy chain of claim 9 , wherein the CH1 domain, remainder of the hinge domain, if any, CH2 domain and CH3 domain are each selected from the group consisting of human IgG1, human IgG2, human IgG3, and human IgG4.